Prognostic Significance of Peripheral Monocyte Count in Patients with Extranodal Natural Killer/T-cell Lymphoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2013 May 4

PMID 23638998

Citations 27

Authors

Jia-Jia Huang

Ya-Jun Li

Yi Xia

Yu Wang

Wen-Xiao Wei

Ying-Jie Zhu

Tong-Yu Lin

Hui-Qiang Huang

Wen-Qi Jiang

Zhi-Ming Li

Affiliations

Soon will be listed here.

Abstract

Background: Extranodal natural killer/T-cell lymphoma (ENKL) has heterogeneous clinical manifestations and prognosis. This study aims to evaluate the prognostic impact of absolute monocyte count (AMC) in ENKL, and provide some immunologically relevant information for better risk stratification in patients with ENKL.

Methods: Retrospective data from 163 patients newly diagnosed with ENKL were analyzed. The absolute monocyte count (AMC) at diagnosis was analyzed as continuous and dichotomized variables. Independent prognostic factors of survival were determined by Cox regression analysis.

Results: The AMC at diagnosis were related to overall survival (OS) and progression-free survival (PFS) in patients with ENKL. Multivariate analysis identified AMC as independent prognostic factors of survival, independent of International Prognostic Index (IPI) and Korean prognostic index (KPI). The prognostic index incorporating AMC and absolute lymphocyte count (ALC), another surrogate factor of immune status, could be used to stratify all 163 patients with ENKL into different prognostic groups. For patients who received chemotherapy followed by radiotherapy (102 cases), the three AMC/ALC index categories identified patients with significantly different survivals. When superimposed on IPI or KPI categories, the AMC/ALC index was better able to identify high-risk patients in the low-risk IPI or KPI category.

Conclusion: The baseline peripheral monocyte count is shown to be an effective prognostic indicator of survival in ENKL patients. The prognostic index related to tumor microenvironment might be helpful to identify high-risk patients with ENKL.

Citing Articles

Predictive value of pre-treatment T lymphocyte subsets in patients with extranodal natural killer/T-cell lymphoma.

Lu X, Huang K, Chen S, Ji X, Li P Ann Hematol. 2024; 103(11):4621-4635.

PMID: 39196374 DOI: 10.1007/s00277-024-05960-0.

Impact of the peripheral blood inflammatory indices and modified nomogram-revised risk index on survival of Extranodal Nasal-Type Natural Killer/T-Cell lymphoma.

Hou Q, Li H, Liang Y, Yao N, Cao X, Liu J Cancer Biomark. 2023; 39(1):27-36.

PMID: 37522199 PMC: 10977361. DOI: 10.3233/CBM-230067.

The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma.

Guven D, Erul E, Yilmaz F, Yasar S, Yildirim H, Ercan F Eur Arch Otorhinolaryngol. 2022; 280(5):2471-2478.

PMID: 36565325 DOI: 10.1007/s00405-022-07804-x.

New prognostic models for extranodal natural killer T-cell lymphoma, nasal-type using Cox regression and machine learning.

Sun J, Ke X, Zhang M, Wang Y, An F, Zhao Y Transl Cancer Res. 2022; 10(2):613-626.

PMID: 35116395 PMC: 8798130. DOI: 10.21037/tcr-20-3017.

The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma.

Zhang Y, Shi Y, Shen H, Shou L, Fang Q, Zheng X Cancer Cell Int. 2021; 21(1):573.

PMID: 34715862 PMC: 8555175. DOI: 10.1186/s12935-021-02275-2.

References

Li Y, Fang H, Liu Q, Lu J, Qi S, Wang H . Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008; 112(8):3057-64. DOI: 10.1182/blood-2008-05-160176. View

Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi C . Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol. 2011; 35(8):1195-203. DOI: 10.1097/PAS.0b013e31821ec4b5. View

Kim T, Heo D . Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009; 100(12):2242-8. PMC: 11159079. DOI: 10.1111/j.1349-7006.2009.01319.x. View

Smedby K, Hjalgrim H . Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011; 21(5):293-8. DOI: 10.1016/j.semcancer.2011.09.010. View

Yang Q, Zhang W, Yu J, Zhao S, Xu H, Wang W . Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011; 6:77. PMC: 3179701. DOI: 10.1186/1746-1596-6-77. View

Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi M . Immunodeficiency-associated lymphomas. Blood Rev. 2008; 22(5):261-81. DOI: 10.1016/j.blre.2008.03.009. View

Lee J, Suh C, Park Y, Ko Y, Bang S, Lee J . Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2005; 24(4):612-8. DOI: 10.1200/JCO.2005.04.1384. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Wilcox R, Ristow K, Habermann T, Inwards D, Micallef I, Johnston P . The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011; 25(9):1502-9. DOI: 10.1038/leu.2011.112. View

10.

Murashige N, Kami M, Kishi Y, Kim S, Takeuchi M, Matsue K . Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005; 130(4):561-7. DOI: 10.1111/j.1365-2141.2005.05651.x. View

11.

Liang X, Graham D . Natural killer cell neoplasms. Cancer. 2008; 112(7):1425-36. DOI: 10.1002/cncr.23316. View

12.

Sinha P, Clements V, Bunt S, Albelda S, Ostrand-Rosenberg S . Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007; 179(2):977-83. DOI: 10.4049/jimmunol.179.2.977. View

13.

de Leval L, Gaulard P . Pathology and biology of peripheral T-cell lymphomas. Histopathology. 2011; 58(1):49-68. DOI: 10.1111/j.1365-2559.2010.03704.x. View

14.

Datta S, Sarvetnick N . Lymphocyte proliferation in immune-mediated diseases. Trends Immunol. 2009; 30(9):430-8. DOI: 10.1016/j.it.2009.06.002. View

15.

Kim D, Baek J, Chae Y, Kim Y, Kim H, Park Y . Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007; 21(10):2227-30. DOI: 10.1038/sj.leu.2404780. View

16.

Moriai S, Takahara M, Ogino T, Nagato T, Kishibe K, Ishii H . Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res. 2009; 15(22):6771-9. DOI: 10.1158/1078-0432.CCR-09-1052. View

17.

Jaccard A, Hermine O . Extranodal natural killer/T-cell lymphoma: advances in the management. Curr Opin Oncol. 2011; 23(5):429-35. DOI: 10.1097/CCO.0b013e328349aba6. View

18.

Steidl C, Gascoyne R . The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011; 118(10):2659-69. DOI: 10.1182/blood-2011-05-326538. View

19.

Jacobson C, LaCasce A . Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park). 2010; 24(10):936-44. View

20.

Gill H, Liang R, Tse E . Extranodal natural-killer/t-cell lymphoma, nasal type. Adv Hematol. 2011; 2010:627401. PMC: 3018635. DOI: 10.1155/2010/627401. View